阿莫西林剂量与疗程对社区获得性肺炎儿童需抗生素再治疗的影响:CAP-IT随机临床试验
CAP-IT为多中心2×2析因非劣效RCT,纳入824名6月龄以上临床诊断CAP的儿童,出院时口服阿莫西林。低剂量(35-50 mg/kg/d)与高剂量(70-90 mg/kg/d)比较,28天内需抗生素再治疗率分别为12.6%和12.4%(差异0.2%,单侧95%CI -∞至4.0%),3天与7天疗程比较均为12.5%(差异0.1%,单侧95%CI -∞至3.9%),均满足8%非劣效界值。
要点
- 低剂量阿莫西林(35-50 mg/kg/d)与高剂量(70-90 mg/kg/d)在28天内需抗生素再治疗率分别为12.6% vs 12.4%,差异0.2%(单侧95%CI -∞至4.0%),满足8%非劣效界值。
- 结论外推需考虑疾病严重程度、治疗场所、既往抗生素使用及非劣效界值可接受性。
适用人群与场景
- 6月龄及以上、临床诊断社区获得性肺炎(CAP)的儿童,从急诊科或医院病房出院(48小时内)时开始口服阿莫西林 outpatient 治疗。
- 研究纳入英国28家医院和爱尔兰1家医院,2017年2月至2019年4月入组,末次随访2019年5月21日;排除标准原文未提及。
诊断标准与关键阈值
- 临床诊断CAP(原文未提供具体诊断标准或评分界值)。
- 主要终点为随机分组后28天内因呼吸道感染需临床指征的抗生素再治疗;非劣效界值为8%。
处置流程与药物剂量
- 口服阿莫西林低剂量35-50 mg/kg/d或高剂量70-90 mg/kg/d,疗程3天或7天,具体分次频次原文未提及。
- 适用条件为从急诊或病房出院(48小时内)的CAP儿童,出院时开始治疗;目标为降低28天内需抗生素再治疗。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 多中心、2×2析因、非劣效RCT,纳入824名儿童(814名至少接受1剂试验药物),来自英国28家医院和爱尔兰1家医院;中位年龄2.5岁(IQR 1.6-2.7),男性421名(52%),女性393名(48%);主要终点可评估789名(97%)。
- 低剂量 vs 高剂量:主要终点(28天内需抗生素再治疗)发生率12.6% vs 12.4%,差异0.2%(单侧95%CI -∞至4.0%),满足非劣效。
证据类型、等级与局限
- 证据类型:多中心随机对照非劣效试验(RCT);原文未给出证据等级或推荐强度。
- 局限:非劣效界值8%的可接受性需考虑;严重CAP亚组样本量有限;结论外推需考虑疾病严重程度、治疗场所和既往抗生素使用;原文未提及盲法或分配隐藏细节。
对床旁实践的改变
- 对于从急诊或病房出院的CAP儿童,可考虑使用低剂量阿莫西林(35-50 mg/kg/d)替代高剂量(70-90 mg/kg/d),因28天内需再治疗率非劣效。
- 可考虑3天疗程替代7天疗程,但需注意3天疗程组咳嗽持续时间中位延长2天(12天 vs 10天)且咳嗽影响睡眠风险略高(HR 1.2)。
- 严重CAP患儿中低剂量和高剂量、3天和7天的差异未达统计学显著,但点估计不利于低剂量和短疗程,解释需谨慎;不适用于原文未纳入的人群(如6月龄以下)。
指南或共识出处
- CAP-IT Randomized Clinical Trial,发表于JAMA;试验注册号ISRCTN76888927。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear.
OBJECTIVE: To determine whether lower-dose amoxicillin is noninferior to higher dose and whether 3-day treatment is noninferior to 7 days.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, 2 × 2 factorial noninferiority trial enrolling 824 children, aged 6 months and older, with clinically diagnosed CAP, treated with amoxicillin on discharge from emergency departments and inpatient wards of 28 hospitals in the UK and 1 in Ireland between February 2017 and April 2019, with last trial visit on May 21, 2019.
INTERVENTIONS: Children were randomized 1:1 to receive oral amoxicillin at a lower dose (35-50 mg/kg/d; n = 410) or higher dose (70-90 mg/kg/d; n = 404), for a shorter duration (3 days; n = 413) or a longer duration (7 days; n = 401).
MAIN OUTCOMES AND MEASURES: The primary outcome was clinically indicated antibiotic re-treatment for respiratory infection within 28 days after randomization. The noninferiority margin was 8%. Secondary outcomes included severity/duration of 9 parent-reported CAP symptoms, 3 antibiotic-related adverse events, and phenotypic resistance in colonizing Streptococcus pneumoniae isolates.
RESULTS: Of 824 participants randomized into 1 of the 4 groups, 814 received at least 1 dose of trial medication (median [IQR] age, 2.5 years [1.6-2.7]; 421 [52%] males and 393 [48%] females), and the primary outcome was available for 789 (97%). For lower vs higher dose, the primary outcome occurred in 12.6% with lower dose vs 12.4% with higher dose (difference, 0.2% [1-sided 95% CI -∞ to 4.0%]), and in 12.5% with 3-day treatment vs 12.5% with 7-day treatment (difference, 0.1% [1-sided 95% CI -∞ to 3.9]). Both groups demonstrated noninferiority with no significant interaction between dose and duration (P = .63). Of the 14 prespecified secondary end points, the only significant differences were 3-day vs 7-day treatment for cough duration (median 12 days vs 10 days; hazard ratio [HR], 1.2 [95% CI, 1.0 to 1.4]; P = .04) and sleep disturbed by cough (median, 4 days vs 4 days; HR, 1.2 [95% CI, 1.0 to 1.4]; P = .03). Among the subgroup of children with severe CAP, the primary end point occurred in 17.3% of lower-dose recipients vs 13.5% of higher-dose recipients (difference, 3.8% [1-sided 95% CI, -∞ to10%]; P value for interaction = .18) and in 16.0% with 3-day treatment vs 14.8% with 7-day treatment (difference, 1.2% [1-sided 95% CI, -∞ to 7.4%]; P value for interaction = .73).
CONCLUSIONS AND RELEVANCE: Among children with CAP discharged from an emergency department or hospital ward (within 48 hours), lower-dose outpatient oral amoxicillin was noninferior to higher dose, and 3-day duration was noninferior to 7 days, with regard to need for antibiotic re-treatment. However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings.
TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN76888927.
参考来源
- Bielicki, Stöhr, Barratt, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021. PMID: 34726708. doi:10.1001/jama.2021.17843
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。